{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:19Z","timestamp":1790939419284,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T00:00:00Z","timestamp":1215648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> Gefitinib inhibits epidermal growth factor receptor (EGFR) signalling, but may also act by non\u2010EGFR dependent mechanisms. We have investigated the activity of gefitinib in haematological tumour cells, in particular acute myeloblastic leukaemia (AML).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Cytotoxic activity of gefitinib, alone or in combination with standard anti\u2010leukaemic drugs, was assessed by the short\u2010term fluorometric microculture cytotoxicity assay in tumour cells from 117 patients representing five haematological and five non\u2010haematological malignancies. In AML, the EGFR status was analysed by immunochemistry. Gefitinib\u2010induced apoptosis was investigated in a subset of AML samples, as well as in the leukaemia cell line MV\u20104\u201011, using a multiparametric high content screening assay. To confirm activation of caspase\u20103 in cells treated with gefitinib, a blocking test was carried out in which MV4\u201011 cells were pretreated with the specific caspase inhibitor DEVD\u2010FMK.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Gefitinib showed highest cytotoxic activity in AML (<jats:italic>n\u2003<\/jats:italic>=\u200319) with many samples being sensitive at concentrations achievable in clinical practice (&lt;10\u2003\u03bc<jats:sc>M<\/jats:sc>), and no difference between previously untreated and relapsed patients. No correlation between the activity of gefitinib and standard antileukaemic drugs (cytarabine, doxorubicin, etoposide) was observed. Combining gefitinib with these drugs resulted in mainly additive or synergistic (etoposide) effects, with no evidence of sequence dependency. The AML cells did not express the EGFR. Gefitinib induced apoptosis, which was at least partly mediated by activation of the caspase\u20103 pathway.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold>  <jats:italic>In vitro<\/jats:italic>, gefitinib has significant cytotoxic activity in AML by inducing apoptosis through non\u2010EGFR dependent pathways.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01120.x","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T15:05:08Z","timestamp":1215702308000},"page":"344-353","source":"Crossref","is-referenced-by-count":27,"title":["Significant cytotoxic activity <i>in vitro<\/i> of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia"],"prefix":"10.1111","volume":"81","author":[{"given":"Elin","family":"Lindhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Grundmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u00c5leskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0178"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.971.11.3","article-title":"50\u2003years of preclinical anticancer drug screening: empirical to target\u2010driven approaches","volume":"11","author":"Suggitt M","year":"2005","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06219.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(01)00344-4"},{"key":"e_1_2_7_6_2","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling AE","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"e_1_2_7_8_2","first-page":"345","article-title":"Suppression of epidermal growth factor receptor, mitogen\u2010activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa)","volume":"2","author":"Barnes CJ","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00045-X"},{"key":"e_1_2_7_10_2","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD\u20101839 (Iressa), an epidermal growth factor receptor\u2010selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello F","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601550"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.04.010"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707704"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0564"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.57.070188.002303"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0738"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0488"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.379.65.2"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1187"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500204"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V70.1.192.192","article-title":"Growth factor requirements of childhood acute leukemia: establishment of GM\u2010CSF\u2010dependent cell lines","volume":"70","author":"Lange B","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0216-7"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-200403000-00001"},{"key":"e_1_2_7_26_2","first-page":"1","volume-title":"EGFr Kit (clone 31G7), PicTure PlusTM\u2010Poymer Detection: for Immunohistostaining of Epidermal Growth Factor Receptor (EGFr) (package insert)","author":"Zymed Laboratories Inc","year":"2003"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1535-7163.521.3.5","article-title":"Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828","volume":"3","author":"Lovborg H","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100362"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-069856"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.6.679"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.n.014"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0095"},{"key":"e_1_2_7_34_2","first-page":"769","article-title":"Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid\u2010induced granulocytic differentiation","volume":"4","author":"Chen LL","year":"1993","journal-title":"Cell Growth Differ"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1068"},{"key":"e_1_2_7_36_2","first-page":"209","article-title":"Syk is a new target for AML differentiation","volume":"110","author":"Hahn CK","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015487"},{"key":"e_1_2_7_38_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.404.404","article-title":"Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicine and cytarabine (DA) induction and high\u2010dose consolidation in newly diagnosed patients with AML","volume":"106","author":"Stone RM","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_39_2","first-page":"2579","article-title":"Successful treatment of a patient with synchronous advanced non\u2010small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low\u2010dose cytarabine and aclarubicin","volume":"25","author":"Takigawa N","year":"2005","journal-title":"Anticancer Res"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000217423.59831.db"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0388"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.2005.00332.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi910"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.950"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.2.78"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00286-X"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200507000-00007"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01120.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01120.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T03:56:53Z","timestamp":1697342213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01120.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,19]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01120.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01120.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,19]]}}}